Similar articles

• [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].

  Pawelski S. Pawelski S. Acta Haematol Pol. 1995;26(3):263-8. Acta Haematol Pol. 1995. PMID: 8525771 Review. Polish.
• Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.

  Foo WC, Huang Q, Sebastian S, Hutchinson CB, Burchette J, Wang E. Foo WC, et al. Hum Pathol. 2010 Dec;41(12):1802-8. doi: 10.1016/j.humpath.2010.04.019. Epub 2010 Sep 24. Hum Pathol. 2010. PMID: 20869749
• Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

  Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Roberts JD, et al. Clin Lymphoma. 2002 Dec;3(3):184-8. doi: 10.3816/clm.2002.n.025. Clin Lymphoma. 2002. PMID: 12521398 Clinical Trial. No abstract available.
• Fludarabine phosphate: an effective therapy for lymphoid malignancies.

  [No authors listed] [No authors listed] Semin Oncol. 1990 Oct;17(5 Suppl 8):1-78. Semin Oncol. 1990. PMID: 1699278 No abstract available.
• Purine analogs in lymphoproliferative disorders.

  Cheson BD. Cheson BD. Leuk Lymphoma. 1993;11 Suppl 2:153-9. doi: 10.3109/10428199309064276. Leuk Lymphoma. 1993. PMID: 7907252 Review. No abstract available.